Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
KRAS Biochemical Assay-BODIPY-GDP Exchange TR-FRET from US Patent US20240228512: "ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF"
Assay data:70 Active, 62 Activity ≤ 1 nM, 70 Activity ≤ 1 µM, 70 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
IRAK4 Kinase Assay from US Patent US12006303: "Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs"
Assay data:22 Active, 22 Activity ≤ 1 µM, 22 Tested
KRASG12D Nucleotide Exchange Assay from US Patent US20240217982: "KRAS INHIBITORS"
Assay data:39 Active, 36 Activity ≤ 1 µM, 41 Tested
KRAS(G12C) and SOS1 Binding Assay from US Patent US20240208945: "6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES"
Assay data:20 Active, 20 Activity ≤ 1 µM, 20 Tested
SOS1/KRAS-G12D Binding Inhibition Assay from US Patent US20240208909: "SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF"
Assay data:75 Active, 96 Activity ≤ 1 µM, 96 Tested
Biological Assay from US Patent US12018014: "Pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof, and preparation method therefor and application thereof"
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
GTP-KRAS and cRAF Interaction Assay from US Patent US20240199644: "Fused Ring Derivatives Useful as KRAS G12D Inhibitors"
Assay data:16 Active, 4 Activity ≤ 1 nM, 15 Activity ≤ 1 µM, 16 Tested
Surface Plasmon Resonance Assay from US Patent US20240197735: "METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A PD-1 BINDING ANTAGONIST"
Assay data:4 Active, 2 Activity ≤ 1 nM, 4 Activity ≤ 1 µM, 4 Tested
Assay of the Activity of Inhibiting KRASG12D from US Patent US20240174692: "PYRIMIDINE AROMATIC RING COMPOUNDS"
Assay data:10 Active, 3 Activity ≤ 1 nM, 10 Activity ≤ 1 µM, 10 Tested
AlphaScreen Binding Assay from US Patent US20240174690: "ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER"
Assay data:240 Active, 107 Activity ≤ 1 nM, 240 Activity ≤ 1 µM, 240 Tested
HTRF Assay from US Patent US20240174674: "NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF"
Assay data:108 Active, 14 Activity ≤ 1 nM, 108 Activity ≤ 1 µM, 108 Tested
Measurement of FXIa Inhibition from US Patent US20240174633: "CRYSTALLINE FORMS OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUORO-METHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE"
Kinase Assay from US Patent US20240174621: "METHYLQUINAZOLINONE DERIVATIVES"
Assay data:5 Active, 3 Activity ≤ 1 nM, 5 Activity ≤ 1 µM, 5 Tested
IRAK4 TR-FRET assay from US Patent US11992481: "Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases"
Biochemical Functional Assay from US Patent US20240166660: "KRAS G12C INHIBITORS"
Assay data:117 Active, 100 Activity ≤ 1 µM, 126 Tested
Inhibition Test of Compounds on KRAS G12C::SOS1 Binding from US Patent US20240166645: "PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF"
Assay data:3 Active, 3 Activity ≤ 1 µM, 3 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Assay data:13 Active, 13 Activity ≤ 1 µM, 13 Tested
AlphaScreen Assay from US Patent US20240148821: "PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND"
Assay data:1791 Active, 341 Activity ≤ 1 nM, 1791 Activity ≤ 1 µM, 1791 Tested
HCK Kinase Assay from US Patent US11963960: "Compounds for treating or inhibiting recurrence of acute myeloid leukemia"
Assay data:8 Active, 8 Activity ≤ 1 µM, 8 Tested
Cdc42 and Rheb GTP Binding Domain Inhibition Assa from US Patent US20240124483: "Methods for the Treatment of Fibrotic Disease"
Assay data:3 Active, 3 Tested
SummaryCompounds, ActiveRelated BioAssays by Target
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on